European Epidemiological Forum - Relatori

Christian J. Agboton currently serves as Senior Global Brand Medical Director at Takeda based in Zurich, Switzerland. He previously served as Medical Director of Biosimilars Immunology / inflammation at Sandoz and Hospira/Pfizer. Christian also worked at GSK vaccines, Merck Serono and UCB Pharma in Clinical and Medical Affairs roles. Channeling innovation to deliver evidence while keeping quality and timelines has always been at the heart of his approach to data generation. Christian is Fellow of the Royal Faculty of Pharmaceutical Medicine (FFPM).

Dr. Maurille Feudjo Tepie is an Observational Research Director at Amgen and leads the Amgen European Team of the Centre for Observational Research. Prior to joining Amgen in 2009, he spent six years in the Worldwide Epidemiology Department at GSK. Maurille obtained his PhD in Medical Statistics from the London School of Hygiene and Tropical Medicine and then completed a one year post-doctoral fellowship working on a collaborative methodological project between the Worldwide Epidemiology Department of GSK and the London School of Hygiene and Tropical Medicine, under the supervision of Profs Stuart Pocock and Steven Evans. He has considerable experience designing and executing appropriate observational research strategies to inform drug development and drug commercialization and; is a keen contributor to scientific discussions pertaining to the challenges and/or opportunities offered to regulators, payers, academics, prescribers and to the bio-pharmaceutical industry by advances in computing science and the increased availability of real world data. He has been active in European-wide initiatives aimed at improving biomedical research (IMI PROTECT and EMIF) and is also the chair of the PSI Epidemiology Special Interest Group.

Michele Intorcia is currently HEOR Senior Director at Apellis Pharmaceuticals. He holds a Master of Science in International Health Policy from London School of Economics and worked in Public Health and Academia. With 16 years experience in the Pharmaceutical Industry he formerly worked for Bristol Myers Squibb, Amgen and established the HEOR Team at Vifor Pharma. He focuses on the evidence generation and pharmacoeconomics strategies to secure access and reimbursement for innovative drugs.

Qualified with a hospital pharmacy background, Omar has been working as the Formulary Advisor for Surrey & Sussex Healthcare NHS Trust for over 15 years, sitting on the regional Joint Drugs & Therapeutics Committee as well as the CCG/Commissioning Prescribing Clinical Network.
Omar has been a visiting Lecturer at UCLH Pharmacy Programme and was both Lecturer & Examiner on the Independent Prescribing V300 Course at the University of Surrey and has over 30 publications to date. He has been appointed as Visiting Lecturer on Value Based Pricing & Innovative Contracting at the University of Portsmouth, is an Editorial Content Adviser to Guidelines, and has recently been invited to the position of Associate Editor to the Canadian Journal of Population Therapeutics & Clinical Pharmacology.
Omar has served a position on the External Reference Group on Cost Impact Modelling for NICE for 6 years and was subsequently appointed Panel Member for the newly formed Adoption & Impact Program Reference for NICE. He advises foreign investors (US Embassy) on ‘Value Based Assessments (hosted by the UK Department of Trade & Industry) and recently delivered a Healthcare NHS Reform program to over 40 Healthcare Insurance Provider delegates visiting from the US.
Last year he was invited to address the Italian Healthcare Senate [Senato della Repubblica] on Pharmaco-economic Evaluation & Sustainability Models of Healthcare and featured at the Westminster Health Forum Keynote Seminars [chaired by Lord Howe, All Party Parliamentary Group on Pharmacy] on the Future for Pharmacy Commissioning, Organisation & Delivery.
At this current time he has embarked on a PhD with his doctorate thesis entitled “Value Based Pricing & Outcomes Based, Innovative Contracting of New Medicines”.

Raquel Billiones has a PhD in Biology and more than 25 years combined experience in scientific and clinical research. She has been a medical writer for >15 years, with core competencies in writing clinical trial and regulatory documents for pharmaceuticals and medical devices. Her core competencies include clinical trials and submissions documents, and data transparency and public disclosure balanced with data protection. Over the years, she took on a wide range of industry positions, as freelancer, as employed regulatory writer, and as head of medical writing departments in the CRO, biotech and big pharma settings. Raquel is an active EMWA member since 2006, serving in various roles. She is currently the Editor-in-Chief of the EMWA journal Medical Writing. She also serves on the Education Committee and the Executive Board of EMWA. She is currently employed as Associate Director, Medical Writing, Alexion Pharmaceuticals (AstraZeneca RareDisease).

Adrian leads the central data and analytics team in the UK National Institute for Health and Care Excellence (NICE). This provides central oversight, advice and support on all aspects of data and analytics; spearheading the transformation programme to enable more sophisticated collection, management, storage and exploitation of data across NICE to enable better evidence based decisions across all its business. Adrian joined NICE in 2018 following ten+ years working in a variety of roles in central government including:

• Assistant Director Strategic and Cross-Cutting Policy within HMRC
• Principal Analyst for Home and Foreign Affairs (Prime Minister’s Implementation Unit) & Head of Profession for Operational Research within the Cabinet Office;
• Head of Analysis and Management Information within the Foreign and Commonwealth Office.

Christian is a consultant pharmacist for medical information. He holds a Diploma in pharmaceutical technology from University of Leipzig and PhD in Medical Sciences of Charité University Medicine of Berlin. After several years working in public pharmacies he joined Riemser Arzneimittel AG as Medical Advisor. He gained broad experiences in Medical Information, Medical Marketing, Clinical Operations and as Information officer. From 2012 to 2014 he has set up the German Operational Business Unit of LA-SER Analytica, a French CRO specialized in the management of pharmacoepidemiological studies. In 2014 he took over the responsibility of Non-Interventional Studies Team and in 2018 the responsibility of Data Generation Team of BAYER Vital GmbH in Leverkusen, Germany. In this position he drives digitalization and innovation in observational study conduct at BAYER.

Biography available soon

Biography available soon